Assessing optimal promoter activity for constructs in gastrointestinal gene therapy.

Assessing optimal promoter activity for constructs in gastrointestinal gene therapy. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Assessing optimal promoter activity for constructs in gastrointestinal gene therapy. Abstract Text:

Rabea Mathlouthi,Susanne Aberle,Nicola Schug,Jan H ,Kristina ,Gerhard Seitz,Nikolaus Blin,

BACKGROUND: During recent decades, studies of various cancer-related genes has led to a growing understanding of molecular mechanisms of gastrointestinal cancer resulting in a genetic progression model. Nevertheless, with a few exceptions, our knowledge of participating genes has not been exploited for gene therapeutic approaches. Therefore, we monitored the promoter activity of genes shown to be significantly expressed in gastrointestinal tumors to select optimally active promoters for recombinant DNA constructs. Such molecules will contain a suicide gene under a suitable cell type-specific regulatory element. MATERIALS AND METHODS: Using promoter-reporter gene (luciferase) constructs we compared the activities of KRT19, TFF1, SEL1L, MUC4, MUC1, CEL and hTERT by transfecting them into the gastrointestinal cell lines MKN45 and DAN-G for transient expression. Furthermore we tested the endogenous expression of these genes by RT-PCR. RESULTS: From a selection of 9 promoter constructs SEL1L, KRT19 and MUC1 displayed the highest activity levels while others were moderately expressed. CONCLUSION: These three appear the most capable ones to drive suicide genes, like thymidine kinase or cytosine deaminase, a study presently initiated.

Assessing optimal promoter activity for constructs in gastrointestinal gene therapy. Publishing Authors By Initials

R Mathlouthi,S Aberle,N Schug,JH ,K ,G Seitz,N Blin,

For similar proteins: neoplasm proteins: tumor suppressor proteins research abstracts see: proteins: neoplasm proteins: tumor suppressor proteins research

PUBMED ID PMID:

MEDLINE DATE: 2003 Sep-Oct

Assessing optimal promoter activity for constructs in gastrointestinal gene therapy. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Anticancer research

VOLUME: 23

Page Numbers: 4011-5

Journal Abbreviation: Anticancer Res.

ISSN: 0250-7005

DAY: 30

MONTH: 11

YEAR: 2007

Assessing optimal promoter activity for constructs in gastrointestinal gene therapy. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8102988

Assessing optimal promoter activity for constructs in gastrointestinal gene therapy. Keywords Mesh Terms:

KEYWORDS: Tumor Suppressor Proteins

MESH TERMS: genetics

Chemical & Substance for Abstract: Assessing optimal promoter activity for constructs in gastrointestinal gene therapy. Information

Substance Name: Telomerase

Registry Number: EC 2.7.7.49

Grant and Affiliation Information for Assessing optimal promoter activity for constructs in gastrointestinal gene therapy.

AFFILIATION: Division of Molecular Genetics, University of Tübingen, Wilhelmstr 27, D-72074 Tübingen, Germany.

Country: Greece

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Anticancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Assessing optimal promoter activity for constructs in gastrointestinal gene therapy Related Publications

• A randomized clinical trial comparing doses and efficacy of lormetazepam tablets or oral solution for insomnia in a general practice setting.
• Aberrant epigenetic patterns in the etiology of gastrointestinal cancers.
• Amygdala activation modulated by levodopa during emotional recognition processing in healthy volunteers: a double-blind, placebo-controlled study.
• Assessing optimal promoter activity for constructs in gastrointestinal gene therapy.
• Compression bandages: influence of techniques of use on their clinical efficiency and tolerance.
• Effect of risperidone versus haloperidol on emotional responding in schizophrenic patients.
• Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice.
• Giant aneurysm of the proximal segment of the left anterior descending artery in a patient with Behçet's disease--a combined approach.
• Lack of Tff3 peptide results in hearing impairment and accelerated presbyacusis.
• Neural bases of different cognitive strategies for facial affect processing in schizophrenia.
• The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer.
• [Cardiac insufficiency: clinical study]
• [Not Available.]
• [Psychomotor retardation associated to depression differs from that of normal aging.]
• [Sexual behaviour in schizophrenic patients: the impact of antipsychotics.]
• [Survey of a pediatrics establishment.]
• [THE TECHNICAL EQUIPMENT OF THE HEART SURGERY GROUP OF THE BROUSSAIS HOSPITAL.]